ATE405838T1 - Gebundene ligande und deren verwendung - Google Patents

Gebundene ligande und deren verwendung

Info

Publication number
ATE405838T1
ATE405838T1 AT00988164T AT00988164T ATE405838T1 AT E405838 T1 ATE405838 T1 AT E405838T1 AT 00988164 T AT00988164 T AT 00988164T AT 00988164 T AT00988164 T AT 00988164T AT E405838 T1 ATE405838 T1 AT E405838T1
Authority
AT
Austria
Prior art keywords
domain
ligand
bonded ligands
receptor
reagents
Prior art date
Application number
AT00988164T
Other languages
English (en)
Inventor
Thomas Schall
Brett Premack
Zhenhua Miao
Zheng Wei
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Application granted granted Critical
Publication of ATE405838T1 publication Critical patent/ATE405838T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00988164T 1999-12-20 2000-12-18 Gebundene ligande und deren verwendung ATE405838T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17297999P 1999-12-20 1999-12-20
US18662600P 2000-03-03 2000-03-03
US09/721,908 US6699677B1 (en) 1999-12-20 2000-11-24 Tethered ligands and methods of use

Publications (1)

Publication Number Publication Date
ATE405838T1 true ATE405838T1 (de) 2008-09-15

Family

ID=27390216

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00988164T ATE405838T1 (de) 1999-12-20 2000-12-18 Gebundene ligande und deren verwendung

Country Status (9)

Country Link
US (1) US6699677B1 (de)
EP (1) EP1247103B1 (de)
JP (1) JP4777570B2 (de)
AT (1) ATE405838T1 (de)
AU (1) AU2440001A (de)
CA (1) CA2390690C (de)
DE (1) DE60040019D1 (de)
ES (1) ES2311485T3 (de)
WO (1) WO2001046698A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39849E1 (en) 1999-10-12 2007-09-18 Chemocentryx, Inc. Methods for identifying modulators of CCX CKR activity
US6998239B1 (en) * 1999-10-12 2006-02-14 Chemocentryx, Inc. Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine
US6780602B2 (en) * 2001-11-01 2004-08-24 Microbiosystems, Limited Partnership Taxonomic identification of pathogenic microorganisms and their toxic proteins
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
JP2005528921A (ja) * 2002-06-10 2005-09-29 メタボレックス インコーポレーティッド Ｃｘ３ｃｒ１修飾物質を用いる糖尿病の治療および診断の方法
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
WO2005003326A2 (en) 2003-03-28 2005-01-13 Receptors Llc. Artificial receptors including reversibly immobilized building blocks and methods
US20040115634A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
US7981694B2 (en) * 2003-01-28 2011-07-19 The Regents Of The University Of California Solid phase isolation of proteins, nucleic acids and other macromolecules
GB0306428D0 (en) * 2003-03-20 2003-04-23 Oxagen Ltd Receptor proteins
DE602004015299D1 (de) * 2003-08-12 2008-09-04 Philips Intellectual Property Verschlussvorrichtung für einen behälter
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
DK2211183T3 (da) * 2003-11-19 2013-05-13 Satoris Inc Fremgangsmåde til diagnosticering og overvågning af Alzheimer's sygdom
WO2006029234A1 (en) * 2004-09-03 2006-03-16 Receptors Llc Combinatorial artificial receptors including tether building blocks
US7985715B2 (en) 2004-09-11 2011-07-26 Receptors Llc Combinatorial artificial receptors including peptide building blocks
US7585968B2 (en) 2005-03-28 2009-09-08 Isis Pharmaceuticals, Inc. Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
US20060258610A1 (en) * 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
WO2007005715A2 (en) * 2005-07-01 2007-01-11 Inhibtex, Inc. Staphylococcal antibodies which cross-react with fungal antigens
MX2009006398A (es) 2006-12-12 2009-06-23 Biorexis Pharmaceutical Corp Genotecas de proteinas de fusion de transferrina.
US8846639B2 (en) * 2008-04-04 2014-09-30 Isis Pharmaceutical, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
US9163094B2 (en) 2011-09-27 2015-10-20 Massachusetts Institute Of Technology Light-activated fusion proteins and uses therefor
AU2013313026A1 (en) 2012-09-06 2015-04-16 Adelaide Research & Innovation Pty Ltd Methods and products for preventing and/or treating metastatic cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6393994A (en) 1993-02-19 1994-09-14 Arris Pharmaceutical Corporation Thin film hpmp matrix systems and methods for constructing and displaying ligands
JPH07147987A (ja) 1993-05-28 1995-06-13 Wisconsin Alumni Res Found ユビキチン接合性酵素（ｅ２）融合タンパク質
US5763199A (en) 1994-09-29 1998-06-09 Mount Sinai School Of Medicine Of The City University Of New York Platelet blockade assay
US5817527A (en) 1995-11-06 1998-10-06 Chiron Diagnostics Corporation Conjugation of ligand to immobilized protein in organic solvent
WO1997027299A1 (en) 1996-01-24 1997-07-31 Schering Corporation Mammalian cx3c chemokine genes
AU7164998A (en) 1997-04-28 1998-11-24 B-E Safe, Inc. Taxonomic identification of microorganisms, proteins and peptides involved in vertebrate disease states

Also Published As

Publication number Publication date
US6699677B1 (en) 2004-03-02
WO2001046698A3 (en) 2002-02-21
JP4777570B2 (ja) 2011-09-21
ES2311485T3 (es) 2009-02-16
EP1247103A2 (de) 2002-10-09
DE60040019D1 (de) 2008-10-02
CA2390690C (en) 2010-08-10
JP2003518138A (ja) 2003-06-03
CA2390690A1 (en) 2001-06-28
WO2001046698A2 (en) 2001-06-28
AU2440001A (en) 2001-07-03
EP1247103B1 (de) 2008-08-20

Similar Documents

Publication Publication Date Title
ATE405838T1 (de) Gebundene ligande und deren verwendung
Kong et al. FRET measurements of cell-traction forces and nano-scale clustering of adhesion ligands varied by substrate stiffness
Stern et al. Label-free electronic detection of the antigen-specific T-cell immune response
CN1158526C (zh) 分析物的化验装置和方法
Helmke et al. Designing a nano-interface in a microfluidic chip to probe living cells: challenges and perspectives
WO2001042786A3 (en) System for cell based screening : cell spreading
TW200514979A (en) Biosensor
GB2347223B (en) Method of electrochemical analysis of an analyte
GB2433987A (en) Methods and systems for detecting biomolecular binding using terahertz radiation
AU4372599A (en) Material for differently modifying the optical properties of different cells
AU6834700A (en) Device and method for determining multiple analytes
AU3260299A (en) Immunoassays involving surface enhanced raman scattering
DE69723860D1 (de) VERFAHREN ZUR BESTIMMUNG VON IgE
US7658825B2 (en) Measuring device and measuring method for detecting analytes
ATE438853T1 (de) Diagnostische testvorrichtung
ITRM20030386A1 (it) Metodo e test diagnostici basati sull'analisi citofluorimetrica dei linfociti t antigene-specifici.
ATE527543T1 (de) Testvorrichtung zur schnelldiagnose
TW200504365A (en) Adhered membranes retaining porosity and biological activity
WO2004057341A3 (en) Cvd assay
Cong et al. Microfluidic device-based in vivo detection of PD-L1-positive small extracellular vesicles and its application for tumor monitoring
SE0401033D0 (sv) Device and method for protein analysis
ATE553386T1 (de) Bluttypisierung
WO2001042503A3 (en) Apparatus and methods for drug screening based on nucleic acid analysis
NZ511217A (en) Method for measuring cellular adhesion
EP1118622A4 (de) Neue antikörper, arzneistoffe die diese enthalten und methoden zum screening von verbindungen unter verwendung dieser antikörper

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties